Cellectar gets FDA rare pediatric disease designation for CLR 131 to treat osteosarcoma
The CLR 131 is an investigational radioiodinated PDC therapy, which exploits the tumor-targeting properties of the firm’s phospholipid ether (PLE) and PLE analogs to selectively deliver radiation to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.